Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexanabinol in Severe Traumatic Brain Injury
NCT00129857Phase 3Completed
- Sponsor
- Pharmos Corporation
- Start
- Jan 2001
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in traumatic brain injury (TBI) comparing Dexanabinol with Placebo (2 arms). Primary endpoint: Glasgow Outcome Scale Extended at 6 months. Started Jan 2001; status: completed.
02
Drugs
Dexanabinol
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT00129857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129857.